Tendinopathy Rare and Atypical Presentations: A Clinical Guide

What Makes a Tendinopathy Presentation "Atypical"?

A tendinopathy is atypical when pain, structural change, or rupture occurs without a clear mechanical trigger, affects bilateral or non-load-bearing tendons, presents in unusual anatomical sites, or fails to follow the expected load-response timeline. These cases account for a minority of clinical visits but carry a disproportionate risk of missed systemic diagnosis.

The standard tendinopathy model, built on repetitive mechanical overload leading to failed healing and collagen disorganization, fits most Achilles, patellar, and rotator cuff presentations seen in active adults [1]. When that model breaks down, the clinician needs a different checklist.

Flags That Should Trigger an Extended Workup

Look for these patterns before attributing pain to mechanical overuse alone:

• Bilateral simultaneous tendon involvement at the same anatomical site
• Tendon symptoms in a sedentary or minimally active patient
• Recent fluoroquinolone, statin, or aromatase inhibitor prescription
• Tendon thickening visible on physical exam without trauma history
• Personal or family history of premature cardiovascular disease
• Recurrent tendinopathy across multiple sites over months

A 2021 systematic review in the BMJ Open found that clinicians identify a systemic cause in fewer than 10% of initial tendinopathy consultations, suggesting significant under-recognition [2].

Why the Distinction Matters Clinically

Treating a metabolic or drug-induced tendinopathy with progressive loading alone can delay recovery by months and, in fluoroquinolone cases, may accelerate structural failure. The 2023 American College of Rheumatology guidance on musculoskeletal soft-tissue disorders recommends excluding systemic etiologies before initiating rehabilitation-only protocols in patients with bilateral or recurrent presentations [3].

Fluoroquinolone-Associated Tendinopathy and Rupture

Fluoroquinolone antibiotics, including ciprofloxacin, levofloxacin, and moxifloxacin, carry an FDA Black Box Warning for tendinopathy and tendon rupture first issued in 2008 and strengthened in 2016 [4]. The Achilles tendon is involved in approximately 90% of reported cases, though the quadriceps, rotator cuff, and biceps tendons are also affected.

A large Danish cohort study (N=46,930 fluoroquinolone users) found a 3.7-fold increase in Achilles tendon rupture risk compared with matched controls not using the antibiotic [5]. Risk climbs further in patients over age 60, those on concurrent systemic corticosteroids (hazard ratio approximately 6.2 in some series), and renal transplant recipients.

Mechanism of Fluoroquinolone Tendon Toxicity

Fluoroquinolones chelate magnesium ions within tenocyte mitochondria, impairing ATP synthesis and triggering reactive oxygen species production. In vitro studies show dose-dependent tenocyte apoptosis within 24 hours of ciprofloxacin exposure at clinically relevant concentrations [6]. Collagen type I synthesis drops measurably, and matrix metalloproteinase-13 activity rises, producing net matrix degradation even before the patient reports pain.

This mechanism explains why symptoms can appear during the course of antibiotics or up to several months after the final dose. Median onset in pharmacovigilance databases is 15 days from the start of treatment, but delayed presentations at 90 days or beyond are well documented [4].

Clinical Recognition and Management

The presentation often lacks prodromal stiffness. Patients describe acute or subacute pain without a precipitating loading event. Ultrasound typically shows tendon thickening, hypoechogenicity, and neo-vascularization on power Doppler, mirroring mechanical tendinopathy histologically but with a steeper rate of structural deterioration.

Management requires:

1. Immediate cessation of the fluoroquinolone if clinically safe and an alternative antibiotic exists
2. Off-loading the affected tendon for a minimum of 2 to 4 weeks
3. No corticosteroid injection into or around the affected tendon
4. Graduated return to load only after imaging confirms structural stabilization, typically 8 to 12 weeks

Patients who re-challenge with a fluoroquinolone after a prior tendon event face a substantially higher rupture risk. This should be documented clearly in the medical record.

Tendon Xanthomas and Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is an autosomal dominant LDL receptor defect affecting roughly 1 in 250 people globally, though most cases go undiagnosed for years [7]. Tendon xanthomas, lipid deposits within the tendon substance, develop in 20 to 50% of untreated heterozygous FH patients and are nearly universal in the homozygous form.

The Achilles tendon is the most common site, but xanthomas also appear in the extensor tendons of the hands, the patellar tendon, and the triceps. On MRI, they appear as focal or diffuse areas of intratendinous signal change, indistinguishable from degenerative tendinopathy without the clinical context of elevated LDL and family history [8].

Why Xanthomas Are Frequently Missed

Most patients do not report pain in the early xanthoma stage. The tendon feels thickened on palpation but is not tender unless secondary mechanical irritation develops. A clinician focused on a painful tendon may order imaging, see signal change, diagnose tendinopathy, and never check a lipid panel.

The Simon Broome Register criteria for FH diagnosis, used across European and UK practice, explicitly include tendon xanthomas as a definitive diagnostic feature when combined with an LDL >4.9 mmol/L [9]. Meeting these criteria should trigger statin therapy and cascade family testing.

Statin Therapy and Tendon Health in FH

Statins lower LDL and slow xanthoma deposition, but they also carry their own tendon risk. A 2019 meta-analysis (N=31,000 patients across 12 trials) found a modest but statistically significant association between statin use and tendinopathy incidence (OR 1.38, 95% CI 1.14 to 1.67) [10]. The net benefit in FH is unambiguously in favor of statins given cardiovascular risk, but this interaction means clinicians should monitor tendon symptoms after statin initiation and consider dose adjustment rather than abrupt cessation if tendinopathy emerges.

Endocrine and Metabolic Causes of Tendinopathy

Several endocrine disorders alter tendon matrix biology through distinct pathways, each producing atypical clinical patterns.

Hypothyroidism

Thyroid hormone regulates tenocyte metabolism and collagen synthesis. In overt hypothyroidism, tendon ground substance accumulates mucopolysaccharides, producing a thickened, edematous tendon visible on ultrasound as diffuse hypoechogenicity without the focal nodular changes typical of mechanical tendinopathy [11]. Patients may report diffuse tendon stiffness and aching rather than the activity-linked pain of mechanical overuse.

Achilles tendon thickening measured by ultrasound correlates with TSH level in euthyroid and subclinical hypothyroid patients, suggesting a dose-response relationship between thyroid dysfunction and tendon change [11]. Replacing thyroid hormone with levothyroxine often reduces tendon thickening over 6 to 12 months, providing a useful diagnostic-therapeutic test.

Diabetes and Advanced Glycation End-Products

Type 2 diabetes increases tendinopathy risk through accumulation of advanced glycation end-products (AGEs) that cross-link collagen fibrils, reducing tendon elasticity and making it susceptible to microtear at lower loads. A prospective cohort study (N=3,590) published in the Journal of Clinical Endocrinology and Metabolism found that patients with HbA1c above 7.5% had a 2.1-fold higher incidence of rotator cuff tendinopathy than normoglycemic controls over a 5-year follow-up [12].

These tendons also heal more slowly after injury. The vascular compromise and neuropathy associated with diabetes reduce both the inflammatory phase and the subsequent proliferative response, extending recovery timelines by an estimated 30 to 50%.

Hyperparathyroidism and Gout

Elevated parathyroid hormone increases bone resorption but also affects peritendinous calcium handling. Primary hyperparathyroidism can produce calcium hydroxyapatite deposits within tendons, mimicking calcific tendinopathy on radiographs. The distinction matters because hyperparathyroidism requires parathyroidectomy in symptomatic cases, not physiotherapy.

Gout produces urate crystal deposition within tendons and peritendinous bursae. The Achilles, peroneal, and extensor tendons of the foot are common sites. Ultrasound shows a characteristic double-contour sign or hyperechoic aggregates, and polarized microscopy of aspirated material confirms the diagnosis. Urate-lowering therapy with allopurinol or febuxostat targeting serum urate below 6 mg/dL reverses intratendinous deposits over 12 to 24 months in most patients [13].

Inflammatory Arthropathy and Enthesopathy

Psoriatic Arthritis and Spondyloarthropathy

Enthesopathy, inflammation at the tendon-bone insertion, is a defining feature of psoriatic arthritis and the broader spondyloarthropathy family (ankylosing spondylitis, reactive arthritis, and IBD-associated arthropathy). Histologically, entheseal tissue in these conditions shows the same failed-healing pattern as mechanical tendinopathy, but driven by innate immune activation rather than load [14].

The Assessment of Spondyloarthritis International Society (ASAS) criteria include enthesitis as a clinical domain. Clinicians should screen for skin psoriasis, inflammatory back pain (worse at rest, improves with activity), uveitis, and oral ulcers when a patient presents with tendinopathy that lacks a mechanical explanation or involves multiple entheses simultaneously.

Ultrasound-detected enthesopathy is present in 30 to 50% of psoriatic arthritis patients even in clinically asymptomatic tendons, suggesting subclinical involvement is widespread [14]. Biologic therapy targeting TNF-alpha or IL-17A substantially reduces ultrasound-detected entheseal abnormality scores, confirming the inflammatory driver.

Rheumatoid Arthritis and Tendon Rupture

Rheumatoid arthritis produces synovial pannus that can invade adjacent tendon sheaths and erode tendon substance. Extensor tendon rupture at the wrist (the "Vaughan-Jackson syndrome," beginning with rupture of extensor digiti minimi and progressing radially) is a well-described atypical presentation that may be the first sign of poorly controlled disease [15]. Patients with RA who develop new finger drop without neurologic cause need urgent orthopedic and rheumatologic evaluation.

Bilateral Spontaneous Tendon Rupture

Simultaneous or sequential bilateral rupture of the same tendon, particularly the quadriceps or patellar tendon, is rare in the general population but is a near-pathognomonic sign of systemic disease when it occurs. A 2018 case series and literature review (N=89 bilateral quadriceps ruptures) found that 63% had an identifiable systemic condition: chronic kidney disease, hyperparathyroidism, systemic lupus erythematosus, diabetes, or prolonged corticosteroid use [16].

Chronic kidney disease (CKD) stages 4 and 5 produce secondary hyperparathyroidism and uremic toxin accumulation, both of which degrade tendon collagen integrity. Dialysis patients face a particularly high risk. In one single-center analysis, bilateral Achilles tendon rupture occurred at a rate 30 times higher in hemodialysis patients than in age-matched controls from the general population [16].

The HealthRX Atypical Tendinopathy Screening Framework provides a structured decision tree for primary care and sports medicine clinicians encountering bilateral or non-mechanical tendinopathy. The framework integrates drug exposure history, metabolic panel findings, and imaging features to direct the workup before rehabilitation begins. (Editorial note: original framework figure to be inserted at review.)

Calcific Tendinopathy: Beyond the Rotator Cuff

Calcific tendinopathy is most commonly discussed in the context of the rotator cuff, where hydroxyapatite deposits affect supraspinatus in roughly 7% of adults on population imaging studies [17]. Atypical calcific presentations, those occurring outside the rotator cuff, are less recognized but clinically significant.

Uncommon Anatomical Sites

Calcific deposits have been documented in the following locations, each posing distinct diagnostic challenges:

• Gluteus medius and minimus insertions: can mimic trochanteric bursitis; hip abductor weakness is the clue
• Flexor carpi ulnaris at the pisiform: mimics triangular fibrocartilage complex pathology on wrist MRI
• Longus colli at C1-C2: presents as acute anterior neck pain with odynophagia and fever, often misdiagnosed as retropharyngeal abscess
• Patellar tendon midsubstance: occurs in younger patients and is frequently associated with metabolic syndrome
• Achilles insertion: distinguished from insertional Achilles tendinopathy by the presence of a well-defined calcific focus on plain radiograph

Calcific tendinopathy of the longus colli deserves specific mention. Acute calcific tendinitis of the longus colli produces a clinical picture of neck pain, low-grade fever, odynophagia, and prevertebral edema on CT that mimics a surgical emergency [18]. CT showing calcific deposits at C1 without ring-enhancing fluid collection distinguishes it from abscess, and it resolves with NSAIDs alone over 1 to 4 weeks.

Treatment Considerations for Atypical Calcific Sites

Ultrasound-guided barbotage (needle aspiration and lavage of the calcium deposit) has the strongest evidence base for rotator cuff disease. A Cochrane review (2021) found that barbotage combined with subacromial corticosteroid injection produced greater pain reduction at 4 weeks than sham plus injection (mean difference -1.75 on a 10-point VAS, P<0.001) [19]. Evidence for barbotage at other anatomical sites is limited to case series, but the procedural principles transfer when the deposit is accessible.

Drug Classes Beyond Fluoroquinolones That Affect Tendons

Aromatase Inhibitors

Aromatase inhibitors (anastrozole, letrozole, exemestane) used in estrogen-receptor positive breast cancer cause musculoskeletal symptoms in 35 to 50% of patients, with tendinopathy and tenosynovitis being common components [20]. Estrogen withdrawal reduces tenocyte proliferation and collagen synthesis. The ACR and ASCO both acknowledge arthralgia and tendinopathy as among the primary reasons women discontinue aromatase inhibitor therapy, affecting long-term breast cancer survival outcomes.

A randomized trial published in the Journal of Clinical Oncology (N=121) found that vitamin D supplementation (50,000 IU weekly for 8 weeks, then monthly) reduced musculoskeletal pain scores, including tendon-specific pain, by 2.1 points on a 10-point scale versus placebo (P<0.05) in women on letrozole, though tendon structural outcomes were not separately measured [21].

Systemic Corticosteroids

Long-term systemic corticosteroid therapy impairs tenocyte function and collagen cross-linking. Unlike peritendinous injection risk (which is localized and related to mechanical weakening at the injection site), systemic steroid exposure degrades tendon integrity globally. Patients on prednisone >10 mg daily for more than 3 months should be considered at elevated baseline tendon rupture risk when planning activity or surgical interventions [22].

Isotretinoin

Isotretinoin, used for severe acne, has a documented but under-reported association with musculoskeletal symptoms. A pharmacovigilance study using the WHO VigiBase database identified 387 tendinopathy and tendon rupture reports associated with isotretinoin, predominantly in males aged 15 to 25 [23]. The proposed mechanism involves retinoid receptor modulation of tenocyte differentiation. Clinicians prescribing isotretinoin to competitive adolescent athletes should discuss this risk explicitly.

Imaging Atypical Tendinopathy: What Standard Protocols Miss

Ultrasound Limitations

Standard gray-scale ultrasound detects tendon thickening, hypoechogenicity, and neo-vascularization reliably but can miss early intratendinous lipid deposits (as in FH xanthomas), urate crystal aggregates (which may require specific high-frequency probes), and the diffuse low-level signal changes of hypothyroid tendinopathy.

High-frequency probes (18 to 22 MHz) improve detection of superficial tendon pathology, and a trained musculoskeletal sonographer using dual-energy CT can distinguish urate from calcium hydroxyapatite when the two coexist [13].

MRI and Advanced Techniques

Diffusion-weighted MRI and T2-mapping sequences are being evaluated in research settings for quantifying collagen fiber organization and water content changes that precede visible structural failure. A 2022 study (N=44 Achilles tendons) found that T2-mapping distinguished healthy tendons from those with early degenerative change with a sensitivity of 81% and specificity of 87%, outperforming conventional T2-weighted sequences [24]. These sequences are not yet standard of care but may become part of pre-operative assessment in complex cases.